to study the role of Dll4/Notch signaling in several models of angiogenesis. In vitro treatment of human umbilical vein endothelial cells (HUVECs) with YW152F resulted in upregulation of VEGF ...

Navicixizumab is a delta-like ligand 4 (DLL4)/vascular endothelial growth factor (VEGF) bispecific antibody that targets angiogenesis. It has potential to address resistance to Avastin ...